Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283314892> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4283314892 endingPage "478" @default.
- W4283314892 startingPage "477" @default.
- W4283314892 abstract "Background: Patients with FLT3-mutated relapsed or refractory (R/R) acute myeloid leukemia (AML) have a dismal prognosis. Gilteritinib is a FLT3 tyrosine kinase inhibitor (TKI) recently approved for patients with R/R AML. Aims: We aimed to characterize real-world data regarding gilteritinib treatment in FLT3-mutated R/R AML and to compare outcomes with matched FLT3-mutated R/R AML patients treated with chemotherapy-based salvage regimens. Methods: Survival analysis was performed by Kaplan Meyer with log rank test to compare between subgroups. Cox proportional hazards regression models were fitted to predict effect of covariates on overall survival (OS) and event free survival (EFS). All statistical analyses used 2-sided p value with a threshold of 0.05. Results: Twenty-five patients from six academic centers were treated with gilteritinib for FLT3-mutated R/R AML. The median age was 58 (IQR1-3 47-73) years, 80% (n=20) were treated with a prior intensive induction regimen and 40% of them received prior TKI therapy. After a median time of seven months post gilteritinib initiation (range 1-34), 12 patients (48%) achieved complete response (CR) with gilteritinib (figure 1A). The estimated median overall survival (OS) of the entire cohort was eight (CI 95% 0-16.2) months and was significantly higher in patients who achieved CR compared to those who did not (16.3 months, CI 95% 0-36.2 vs. 2.6 months, CI 95% 1.47-3.7; p value=0.046, figure 1B). In a multivariate cox regression analysis, achievement of CR was the only predictor for longer OS (HR 0.33 95% CI 0.11-0.97, p=0.044). Prior TKI exposure did not affect OS but was associated with better event-free survival (HR 0.15 95% CI 0.03-0.71, p=0.016). An age and ELN-risk matched comparison between patients treated with gilteritinib and intensive salvage revealed similar response rates (50% in both groups); median OS was 9.6 months (CI 95% 2.3-16,8) vs. 7 months (CI 95% 5.1-8.9) in gilteritinib and matched controls, respectively (p = 0.869, figure 1C). Image:Summary/Conclusion: In the real-world setting gilteritinib is effective, including in heavily pre-treated, TKI exposed patients." @default.
- W4283314892 created "2022-06-24" @default.
- W4283314892 creator A5001922074 @default.
- W4283314892 creator A5015040640 @default.
- W4283314892 creator A5021346352 @default.
- W4283314892 creator A5023585815 @default.
- W4283314892 creator A5032731817 @default.
- W4283314892 creator A5032967792 @default.
- W4283314892 creator A5037018787 @default.
- W4283314892 creator A5049059619 @default.
- W4283314892 creator A5053411706 @default.
- W4283314892 creator A5068991790 @default.
- W4283314892 creator A5072468961 @default.
- W4283314892 creator A5085103789 @default.
- W4283314892 creator A5085701502 @default.
- W4283314892 creator A5086557065 @default.
- W4283314892 date "2022-06-01" @default.
- W4283314892 modified "2023-09-30" @default.
- W4283314892 title "P578: GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS" @default.
- W4283314892 doi "https://doi.org/10.1097/01.hs9.0000845200.34626.04" @default.
- W4283314892 hasPublicationYear "2022" @default.
- W4283314892 type Work @default.
- W4283314892 citedByCount "0" @default.
- W4283314892 crossrefType "journal-article" @default.
- W4283314892 hasAuthorship W4283314892A5001922074 @default.
- W4283314892 hasAuthorship W4283314892A5015040640 @default.
- W4283314892 hasAuthorship W4283314892A5021346352 @default.
- W4283314892 hasAuthorship W4283314892A5023585815 @default.
- W4283314892 hasAuthorship W4283314892A5032731817 @default.
- W4283314892 hasAuthorship W4283314892A5032967792 @default.
- W4283314892 hasAuthorship W4283314892A5037018787 @default.
- W4283314892 hasAuthorship W4283314892A5049059619 @default.
- W4283314892 hasAuthorship W4283314892A5053411706 @default.
- W4283314892 hasAuthorship W4283314892A5068991790 @default.
- W4283314892 hasAuthorship W4283314892A5072468961 @default.
- W4283314892 hasAuthorship W4283314892A5085103789 @default.
- W4283314892 hasAuthorship W4283314892A5085701502 @default.
- W4283314892 hasAuthorship W4283314892A5086557065 @default.
- W4283314892 hasBestOaLocation W42833148921 @default.
- W4283314892 hasConcept C10515644 @default.
- W4283314892 hasConcept C126322002 @default.
- W4283314892 hasConcept C141071460 @default.
- W4283314892 hasConcept C142424586 @default.
- W4283314892 hasConcept C2778729363 @default.
- W4283314892 hasConcept C2781413609 @default.
- W4283314892 hasConcept C50382708 @default.
- W4283314892 hasConcept C66339696 @default.
- W4283314892 hasConcept C71924100 @default.
- W4283314892 hasConcept C72563966 @default.
- W4283314892 hasConcept C86803240 @default.
- W4283314892 hasConcept C87355193 @default.
- W4283314892 hasConcept C90924648 @default.
- W4283314892 hasConceptScore W4283314892C10515644 @default.
- W4283314892 hasConceptScore W4283314892C126322002 @default.
- W4283314892 hasConceptScore W4283314892C141071460 @default.
- W4283314892 hasConceptScore W4283314892C142424586 @default.
- W4283314892 hasConceptScore W4283314892C2778729363 @default.
- W4283314892 hasConceptScore W4283314892C2781413609 @default.
- W4283314892 hasConceptScore W4283314892C50382708 @default.
- W4283314892 hasConceptScore W4283314892C66339696 @default.
- W4283314892 hasConceptScore W4283314892C71924100 @default.
- W4283314892 hasConceptScore W4283314892C72563966 @default.
- W4283314892 hasConceptScore W4283314892C86803240 @default.
- W4283314892 hasConceptScore W4283314892C87355193 @default.
- W4283314892 hasConceptScore W4283314892C90924648 @default.
- W4283314892 hasLocation W42833148921 @default.
- W4283314892 hasLocation W42833148922 @default.
- W4283314892 hasOpenAccess W4283314892 @default.
- W4283314892 hasPrimaryLocation W42833148921 @default.
- W4283314892 hasRelatedWork W1968524627 @default.
- W4283314892 hasRelatedWork W2010631330 @default.
- W4283314892 hasRelatedWork W2378838272 @default.
- W4283314892 hasRelatedWork W2383638159 @default.
- W4283314892 hasRelatedWork W2912786681 @default.
- W4283314892 hasRelatedWork W3029923507 @default.
- W4283314892 hasRelatedWork W3136232645 @default.
- W4283314892 hasRelatedWork W4200489086 @default.
- W4283314892 hasRelatedWork W4225121065 @default.
- W4283314892 hasRelatedWork W4235457825 @default.
- W4283314892 hasVolume "6" @default.
- W4283314892 isParatext "false" @default.
- W4283314892 isRetracted "false" @default.
- W4283314892 workType "article" @default.